CHAPTER 1
INTRODUCTION
Terms of Reference
1.1
On 25 November 2009, the Senate referred the following matter to the
Community Affairs References Committee for inquiry and report by 30 June 2010:
Consumer access to pharmaceutical benefits and the creation
of new therapeutic groups through the Pharmaceutical Benefits Scheme (PBS),
including:
(a)
The impact of new therapeutic
groups on consumer access to existing PBS drugs, vaccines and future drugs,
particularly high cost drugs;
(b)
The criteria and clinical evidence
used to qualify drugs as interchangeable at a patient level;
(c)
The effect of new therapeutic
groups on the number and size of patient contributions;
(d)
Consultation undertaken in the
development of new therapeutic groups;
(e)
The impact of new therapeutic
groups on the classification of medicines in F1 and F2 formularies;
(f)
The delay to price reductions
associated with the price disclosure provisions due to take effect on 1 August
2009 and the reasons for the delay;
(g)
The process and timing of
consideration by Cabinet of high cost drugs and vaccines; and
(h)
Any other related matters.
1.2
On 22 June 2010, the reporting date for the inquiry was extended to
26 August 2010.
1.3
On 26 August 2010, the committee tabled a brief report concluding:
On 19 July 2010, the Governor-General prorogued the 42nd
Parliament and dissolve the House of Representatives. After due consideration,
the committee has determined that it is unable to provide a comprehensive
report at this time. The committee will reconsider the issues of this inquiry
in the event that it is re-referred to the committee in the new parliament.[1]
1.4
The evidence received by the committee during the 42nd Parliament was
tabled in the Senate at that time.
1.5
On 30 September 2010, the Senate re-referred the inquiry, with the same
terms of reference, to the committee for inquiry and report by 25 November
2010. The Senate agreed to allow the committee to consider and use the submissions
and oral evidence received by the committee during its inquiry in the 42nd
Parliament.[2]
Conduct of the inquiry
1.6
In accordance with usual practice, the inquiry was advertised in The Australian
and on the internet, inviting submissions by 31 March 2010. The committee also invited
submissions from numerous organisations and individuals.
1.7
Upon re-referral, the inquiry was re-advertised in The Australian
and on the internet, inviting submissions by 20 October 2010. The committee
also invited those organisations and individuals who had made submissions to
the previous inquiry to provide additional information to update or amend their
earlier submissions.
1.8
The committee received 35 submissions, listed at Appendix 1.
1.9
The committee held a public hearing in Canberra on 7 May 2010. The
witnesses are listed at Appendix 2.
Background
The Pharmaceutical Benefits Scheme
1.10
The PBS was created in 1948 and is now enacted by the National Health
Act 1953.[3]
1.11
The scheme enables Australians to access government-subsidised
prescriptions currently at a cost of $33.30 for general patients and $5.40 for
concessional patients.[4]
1.12
There are currently over 740 medicines in more than 1850 forms available
on the PBS.[5]
In 2008-09, approximately 182 million PBS prescriptions were dispensed at a
cost to government of $7.7 billion.[6]
1.13
Before being listed on the PBS, medicines must be considered by the
Pharmaceutical Benefits Advisory Committee (PBAC).[7]
The PBAC is an independent, statutory body comprising health professionals
(doctors, academics, a pharmacist and a health economist) and a consumer
representative.[8]
The PBAC considers the clinical and cost-effectiveness of a medicine in
comparison to other available treatments and provides advice to the Minister
for Health and Ageing as to whether a medicine should be listed on the PBS.[9]
Therapeutic group policy
1.14
The therapeutic group policy, to be applied to some PBS-listed medicines,
was first announced by the Commonwealth Government in the 1997-98 Federal
Budget.[10]
The first four therapeutic groups were created in February 1998 and comprised the:
- angiotensin I converting enzyme (ACE) inhibitors;
- calcium channel blockers (CCBs);
- H2 receptor antagonists (H2RAs), and
- HMG-CoA reductase inhibitors (statins).[11]
1.15
The inclusion of these drugs in therapeutic groups was based on advice
from the PBAC 'that the drugs in each group are very alike and work just as
well as one another for the vast majority of people'.[12]
1.16
The therapeutic group policy does not mean that patients must switch to
a medicine, or switch between medicines, in a therapeutic group because it is
less expensive than a medicine they are already taking.[13]
1.17
Following formation of the therapeutic groups, the government applied
the therapeutic group pricing policy. The pricing policy meant that the government
'paid one level of PBS subsidy for all medicines containing the drugs within
each of the four groups. This applied regardless of whether or not the drugs
had the same PBS listings'.[14]
1.18
The therapeutic group pricing policy has been applied and continues to
apply to all therapeutic groups created since the first groups in 1997-98. In
general terms, the pricing policy ensures that medicines in a therapeutic group
'have the same monthly treatment cost despite variations in prescribed doses'.[15]
1.19
In 2007, during the introduction of a range of reforms to the PBS, the
government formed another two therapeutic groups comprising the angiotensin II
receptor antagonists (A2RAs) and proton pump inhibitors (PPIs).[16]
It was also at this time that the therapeutic group policy was legislated in
the National Health Act 1953 'by providing in the Act, for the first
time, that therapeutic groups are formed by determination in a legislative instrument
made by the Minister'.[17]
1.20
The Department of Health and Ageing (DoHA) advised that:
Under the Act the Minister can form a therapeutic group only
after obtaining advice from the PBAC in relation to the proposed determination.
Further, when deciding on the drugs that comprise a group the Minister may have
regard to any PBAC advice to the effect that a drug should, or should not, be treated
as interchangeable on an individual patient basis with another listed drug. The
PBAC has corresponding functions for providing the advice about formation of groups
and interchangeability of drugs.[18]
1.21
In the 2009-10 Federal Budget, the government announced the creation of a
seventh therapeutic group for the high potency statins (statins-HP).[19]
This group was formed in September 2009.[20]
1.22
On 2 November 2009, the government released the 2009-10 Mid-Year
Economic and Fiscal Outlook (MYEFO) which estimated an increase in expenditure
on health and ageing of $4.8 billion over four years, due in part to
projected expenditure on pharmaceutical benefits.[21]
The MYEFO also announced the establishment of three new therapeutic groups
under the PBS covering venlafaxine and desvenlafaxine derivatives
(anti-depressants) and oral bisphosphonates (for the treatment of osteoporosis
and Paget disease).[22]
The creation of these additional therapeutic groups was anticipated to deliver
savings of $48.2 million over four years, commencing 1 April 2010.[23]
1.23
The three therapeutic groups announced in the 2009-10 MYEFO were formed
with effect from 21 January 2010, with the associated price changes due to come
into effect on 1 April 2010.[24]
1.24
However, on 11 March 2010, before the associated price changes occurred,
the Senate disallowed Parts 8, 9 and 10 of the National Health
(Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 which
provided for the creation of the three therapeutic groups announced in the
MYEFO.[25]
As a result, these three therapeutic groups have not yet come into effect.
Therapeutic group premium
1.25
Drugs in a therapeutic group may be subject to a charge in addition to
the co‑payment amount, known as a 'therapeutic group premium'.[26]
This additional fee is paid by the consumer and only applies to a medicine
where the manufacturer does not accept the PBS price under the therapeutic
group pricing policy.[27]
1.26
However, when prescribing a medicine subject to a therapeutic group
premium, a doctor may apply for a patient to be exempt from paying the premium
on the basis that it would be 'clinically inappropriate for a patient to be
prescribed a different medicine in the therapeutic group in order to avoid a
therapeutic group premium'.[28]
In this circumstance, the Commonwealth Government pays the patient premium
where the prescriber has obtained an authority from Medicare Australia, based
on one of a number of specified criteria (please refer to Chapter 3).[29]
Cabinet consideration of high cost
drugs
1.27
Where a medicine being considered for inclusion on the PBS is estimated
to cost government more than $10 million in any of its first four full years of
PBS listing, a submission on that drug must be considered by Cabinet.[30]
The threshold is intended to ensure that Cabinet ministers are aware of
government expenditure.
1.28
The threshold of $10 million for Cabinet consideration was originally
set in 2002 and has not changed since that time.[31]
1.29
Since November 2007, it has taken on average 7.1 months from PBAC
recommendation to Cabinet consideration of a medicine.[32]
Memorandum of Understanding
1.30
During the course of the inquiry, on 6 May 2010, the Minister for Health
and Ageing and Medicines Australia signed a memorandum of understanding (MOU)
with effect until 30 June 2014. In the MOU, the government undertook not to
create any new therapeutic groups during the period of the MOU (except in
particular circumstances) and agreed to 'provide sponsors with reasonable
notice of its intention to form any new Group, and seek sponsor comment prior to
determination of any new Group'[33]
but stated:
The three Therapeutic Groups which the Commonwealth had
announced an intention to form in the 2009 Mid-Year Economic and Fiscal
Outlook, do not represent new Therapeutic Groups for the purposes of paragraphs
16 and 17 and, thus, are not covered by this MOU. These comprise drugs for the
treatment of depression, osteoporosis, and Paget disease.[34]
1.31
Paragraphs 28 and 29 of the MOU detail the Commonwealth's undertakings with
respect to reducing the period of time taken for Cabinet consideration of high
cost drugs:
The Commonwealth will work with industry to examine possible
methods to reduce the time taken to finalise PBS pricing negotiations after a
PBAC recommendation, including for those PBS submissions that require Cabinet
approval...[35]
And:
For those submissions required to be approved by Cabinet, the
Commonwealth will use its best endeavours to implement a maximum time frame of
six months for consideration and decision by Cabinet. The six months will
commence from the date of notification by the Department of Health and Ageing
to the sponsor that pricing is agreed.[36]
1.32
The MOU also includes 'Resolution of issues in good faith' provisions
which state, in part:
In the event that a dispute occurs between the Commonwealth
and Medicines Australia in relation to the operation of this MOU, and that
cannot be settled in discussion with the relevant Deputy Secretary, the Chief
Executive of Medicines Australia and the Secretary of the Department of Health
and Ageing will meet in the first instance to resolve the issue. In the event
that the dispute is still not resolved, the matter will be referred to a
meeting between the Minister for Health and Ageing and representatives of the
Medicines Australia Board.[37]
Issues raised during the inquiry
1.33
A number of issues were raised during this inquiry including:
- the therapeutic group policy and creation of new therapeutic
groups generally;
- the lack of consultation and transparency during the process of
creating the four new therapeutic groups announced during 2009 in the Federal
Budget and in the 2009-10 MYEFO specifically;
- related to the above, the definition of and evidence for
"interchangeability" for the purpose of creating therapeutic groups;
- the lack of awareness amongst doctors of their ability to seek an
exemption on behalf of a patient from payment of a therapeutic group premium;
-
the $10 million cost threshold for consideration of high cost
medicines by Cabinet; and
- the time taken by Cabinet to consider high cost medicines.
1.34
The issues regarding the creation of further therapeutic groups and the
time taken by Cabinet to consider high cost medicines appear to have been
addressed by the MOU. The other issues regarding the lack of consultation and
transparency; the definition and evidence for interchangeability; the lack of
awareness amongst doctors about exemptions; and the $10 million threshold for
Cabinet consideration remain outstanding and will therefore be examined in the
following chapters of this report.
1.35
Other issues raised during the inquiry regarding reforms to the PBS in
2007 and the pricing of generic medicines, as well as professional services
provided by pharmacists, are discussed in the final chapter of this report.
Navigation: Previous Page | Contents | Next Page